摘要
背景:黄酮木脂素的属名在1968年被创立,它是一种相对较小的天然杂交分子,生物途径起源于无处不在的黄酮和木脂素类化合物(苯丙素)。 黄酮木脂素最先从长期用于肝保护的水飞蓟中萃取得到。近期黄酮木脂素的药用价值拓展到了前列腺癌管理。 方法:相关文献系统性阐述和总结 结果:目前已经从各种植物中获得了天然的超过40种黄酮木脂素。部分黄酮木脂素已经进行了体外细胞和体内动物试验以及人类临床试验,证实了其:(1)具有有效的拮抗各种肿瘤促进剂的化学预防能够;(2)表达出抗血管再生的有效性;(3)对前列腺癌潜在治疗作用;(4)保护或者治疗前列腺癌患者在化疗过程中引起的肝毒性。部分黄酮木脂素能够协同增加化疗作用治疗前列腺癌。 结论:本文对黄酮木脂素在前列腺癌管理方面的潜在前景提供了一个系统的、深入的综述,包括化学预防功能、化疗、作用机制、合成衍生物、构效关系以及黄酮木脂素和相似的独立黄酮两者对抑制前列腺癌细胞增加的不同点。本综述通过结合文献中报道的数据阐述,旨在为前列腺癌管理黄酮木脂素的进一步合理发展提供有价值的见解。
关键词: 前列腺癌;黄酮木脂素;作用机制;化疗制剂;构效关系;黄酮
Current Medicinal Chemistry
Title:The Potential of Flavonolignans in Prostate Cancer Management
Volume: 23 Issue: 34
Author(s): Bao Vue, Qiao-Hong Chen
Affiliation:
关键词: 前列腺癌;黄酮木脂素;作用机制;化疗制剂;构效关系;黄酮
摘要: Background: The generic name “flavonolignan” was created in 1968 for a relatively small class of naturally occurring hybrid molecules biogenetically originated from ubiquitous flavonoids and lignans (phenylpropanoids). The first group of flavonolignans was extracted from Silybum marianum that has long been used for hepatoprotection. Recently, the medicinal merit of flavonolignans has been extended to the prostate cancer management.
Methods: Systematic interpretation and summarization of the relevant literature.
Results: Over forty naturally occurring flavonolignans have so far been obtained from various plants. Certain flavonolignans have been demonstrated by in vitro cell-based and in vivo animal-based experiments, and human clinical studies i) to possess effective chemopreventive function against various tumor promoters; ii) to show the anti-angiogenic efficacy; iii) to have potential in treating prostate cancer; iv) to sensitize prostate tumors to chemotherapeutic agents through down-regulation of P-glycoprotein and other mechanisms; and v) to be used by prostate cancer patients to protect or treat the hepatotoxicity caused by several chemotherapies. Certain flavonolignans can synergize with well-established chemotherapeutic agents for prostate cancer.
Conclusion: This review provides a systematic and in-depth overview of the promise and potential of flavonolignans in prostate cancer management, which covers their chemopreventive effect, chemotherapeutic treatment, mechanisms of actions, synthetic derivatives, structure-activity relationships, and the difference in inhibiting prostate cancer cell proliferation between certain flavonoligans and their respective flavonoid counterpart. This summarization aims to provide valuable insights into further and rational development of flavonolignans for prostate cancer management by interpreting the data reported in the literature.
Export Options
About this article
Cite this article as:
Bao Vue, Qiao-Hong Chen , The Potential of Flavonolignans in Prostate Cancer Management, Current Medicinal Chemistry 2016; 23 (34) . https://dx.doi.org/10.2174/0929867323666160823151833
DOI https://dx.doi.org/10.2174/0929867323666160823151833 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs in Human Diseases
Recent Patents on DNA & Gene Sequences Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Immunotherapy with Dendritic Cells as a Cancer Treatment: Perspectives and Therapeutic Potential
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry Construction of a γ-Butyrolactone Moiety: A Facile Synthesis of 3β- Hydroxy-5,6-Dihydro-17β -Methoxy-Pregnan-21,16α-Carbalactone - a New D-Ring Fused Steroidal γ-Butyrolactone from an Abundant 20- Oxopregnane using Metal Mediated Halogenation as the Key Step
Letters in Organic Chemistry Current Applications of Artificial Neural Networks in Biochemistry with Emphasis on Cancer Research
Current Biochemical Engineering (Discontinued) Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Nonsteroidal Aromatase Inhibitors for the Treatment of Breast Cancer: An Update
Anti-Cancer Agents in Medicinal Chemistry Bisphosphonate Therapy for Patients with Breast Cancer
Current Cancer Therapy Reviews Genetic Association of CUGBP2 and DNMBP with Alzheimer’ s Disease in the Chinese Han Population
Current Alzheimer Research GnRH Agonists and Antagonists in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Current Pharmaceutical Design Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease
Current Molecular Pharmacology Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges
Current Cancer Drug Targets Insights into Immunophilin Structure and Function
Current Medicinal Chemistry Dietary Phenolic Acids and Flavonoids as Potential Anti-Cancer Agents: Current State of the Art and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Utility and Limitations of SP600125, an Inhibitor of Stress-Responsive c-Jun N-Terminal Kinase
Current Enzyme Inhibition Androgen Receptor Coregulatory Proteins as Potential Therapeutic Targets in the Treatment of Prostate Cancer
Current Cancer Therapy Reviews